Enliven Therapeutics climbs 5%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Enliven Therapeutics (ELVN.US) climbed more than 5% during regular trading to $43.68.

The stock is up 10.61% over the past ten sessions and up 183.64% year to date. It sits 195.53% above its 52-week low of US$14.78. Volume was 3.30 times its average.

The Nasdaq Composite is down 0.18% over the past five sessions and up 13.49% year to date.

The company confirmed it has reached a final agreement with the U.S. Food and Drug Administration on the design of the Phase III ENABLE-2 clinical trial for relcobatinib in previously treated chronic myeloid leukemia patients. The study is expected to enroll approximately 450 patients, comparing an 80 mg dose against second-generation tyrosine kinase inhibitors, with major molecular response at week 24 as the primary endpoint.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.